Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of Omacor 4g/day on blood lipid
parameters and on the function and stiffness of blood vessels in HIV infected patients on
Antiretroviral Therapy (HAART)
Phase:
Phase 4
Details
Lead Sponsor:
Pronova BioPharma
Collaborators:
Aalborg Universitetshospital Aalborg University Hospital